Acute Myelogenous Leukemia
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Published in Genetics and Environmental Business Week, June 19th, 2008
At ASCO(R), data were presented in 85 evaluable patients. The median age of these patients was 73 years (range of 60-87 years). Ninety-five percent of patients had two or more risk factors associated with a poor prognosis in elderly AML and 74% had three or more risk factors. The most common risk factors were age greater...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- Alnylam Pharmaceuticals, Inc.
Alnylam Announces Close of Investment and Expanded Agreement Related to the Tekmira-Protiva Business Combination - Amira Pharmaceuticals
Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline - Arthritis
Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings - BioMarin Pharmaceutical Inc.
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio a Syndrome - Biotech Business
Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D - Biotechnology
SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
